logo-loader
FSD Pharma

FSD Pharma closes Prismic Pharmaceuticals acquisition

FSD Pharma Inc (CSE: HUGE) (OTCMKTS:FSDDF) President Edward Brennan tells Proactive Investors the cannabis focused company has closed on a $17.5 million deal to acquire US-based specialty research and development pharma company Prismic Pharmaceuticals Inc.

Dr Brennan also offered investors a glimpse into his professional background which includes stints as the general surgeon at Johnson & Johnson (NYSE:JNJ) and GlaxoSmithKline PLC (NYSE:GSK).

Quick facts: FSD Pharma

Price: $0.10

Market: CSE
Market Cap: $151.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: FSD Pharma expects to report meaningful medical cannabis...

FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) CEO Dr. Raza Bokhari tells Proactive the cannabis company expects to report meaningful medical cannabis sales revenue in 3Q. Dr. Bokhari says last week, the company reported modest 2Q earnings generated mostly from rental leases. Now, Dr. Bokhari...

2 weeks, 1 day ago

2 min read